Weil Guides Bard In $200M Deal For Hemostat Maker Medafor

Law360, New York (August 19, 2013, 2:34 PM EDT) -- New Jersey-based C.R. Bard Inc. will pay some $200 million in cash to purchase Minneapolis-based hemostat firm Medafor Inc. through Bard's specialized surgical procedures unit Davol Inc., the companies said Monday.

Bard will pay the $200 million when the deal closes but may also pay up to $80 million when certain revenue milestones until June 2015 are reached, according to the companies. The deal, which requires regulatory approvals and a blessing from Medafor shareholders, is expected to close by the end of the year.

“With the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.